有机化学 ›› 2021, Vol. 41 ›› Issue (11): 4428-4436.DOI: 10.6023/cjoc202106015 上一篇    下一篇

研究论文

含喹喔啉基咪唑结构的罗丹宁衍生物的合成及其ALK5、抗菌和抗真菌活性研究

韩立卓a, 赵丽敏a, 王慧敏a, 窦桐a, 郭芳妍a, 齐浚答a, 许文博a, 朴莲荀a, 金学军a, 陈芬儿b, 朴虎日b, 郑昌吉b,*(), 金成华a,b,*()   

  1. a 延边大学药学院 分子药物研究中心 吉林延吉 133002
    b 延边大学 长白山天然药物教育部重点实验室 吉林延吉 133002
  • 收稿日期:2021-06-07 修回日期:2021-07-12 发布日期:2021-08-09
  • 通讯作者: 郑昌吉, 金成华
  • 作者简介:
    † 共同第一作者.
  • 基金资助:
    国家自然科学基金(8206023)

Synthesis, Antibacterial and Antifungal Evaluation of Rhodanine Derivatives Bearing Quinoxalinyl Imidazole Moiety as ALK5 Inhibitors

Lizhuo Hana, Limin Zhaoa, Huimin Wanga, Tong Doua, Fangyan Guoa, Junda Qia, Wenbo Xua, Lianxun Piaoa, Xuejun Jina, Fen'er Chenb, Huri Piaob, Changji Zhengb(), Chenghua Jina,b()   

  1. a Molecular Medicine Research Center, College of Pharmacy, Yanbian University, Yanji, Jilin 133002
    b Key Laboratory of Natural Medicines of the Changbai Mountain, Minstry of Education, Yanbian University, Yanji, Jilin 133002
  • Received:2021-06-07 Revised:2021-07-12 Published:2021-08-09
  • Contact: Changji Zheng, Chenghua Jin
  • About author:
    † These authors contributed equally to this work.
  • Supported by:
    National Natural Science Foundation of China(8206023)

转化生长因子-β (TGF-β)在许多疾病中过表达, 是治疗肿瘤的重要靶点. 合成了2个系列3-取代-5-(5-(6-甲基吡啶-2-酰基)-4-(喹啉-6-基)-1氢-咪唑-2-基)亚甲基)-2-噁唑烷-4-酮化合物(1213a~13e14a~14h), 并对其进行了活性受体样激酶5 (ALK5)抑制活性评价. 其中(Z)-6-(5-((5-(6-甲基吡啶-2-基)-4-(喹喔啉-6-基)-1H-咪唑-2-基)亚甲基)-4-羰基-2-硫代羰基噻唑-3-基)己酸(13e)对ALK5激酶的活性最高(IC50=0.451 µmol•L–1), 对p38α激酶的选择性指数大于22, 比临床候选化合物LY-2157299选择性高5.0倍. 在TGF-β抑制剂的研究中发现这些罗丹宁化合物具有良好的抗真菌活性, 而且对革兰氏阳性菌和革兰氏阴性菌显示很高的选择性. 它们显示与阳性对照化合物氟康唑(MIC=1 µg/mL)类似或更高的抗真菌活性(MIC=0.5 or 1 µg/mL).

关键词: 罗丹宁, 转化生长因子-β, 喹喔啉基咪唑, ALK5抑制剂, 抗菌, 抗真菌

Transforming growth factor-β (TGF-β) is overexpressed in many diseases, and is an important target for treating tumors. Two series of 3-substituted-5-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methylene)-2-thioxo- thiazolidin-4-ones (12, 13a~13e, and 14a~14h) were synthesized and evaluated for their activin receptor-like kinase 5 (ALK5) inhibition activity. Among these compounds, (Z)-6-(5-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol- 2-yl)methylene)-4-oxo-2-thioxothiazolidin-3-yl)hexanoic acid (13e) showed the highest activity (IC50=0.451 µmol•L–1) against ALK5 kinase, which had a good selectivity index of >22 against p38α MAP kinase, with 5.0-fold more selectivity than the clinical candidate of LY-2157299. These rhodanine compounds showed good antifungal activity and high selectivity against both Gram-positive and Gram-negative bacteria. These compounds showed similar or higher antifungal activity (MIC=0.5 or 1 µg/mL) to the positive control compound fluconazole (MIC=1 µg/mL).

Key words: rhodanine, TGF-β, quinoxalinyl imidazole, ALK5 inhibitor, antimicrobial, antifungal